Get the latest buzz in the global pharmaceutical market here.
Marksans Pharma Limited’s newly acquired manufacturing facility located at Plot No. A1, Phase l-A, Verna Industrial Estate, Verna, Goa - 403722 has successfully undergone inspection from German health authorities.
Marksans Pharma Limited’s wholly owned subsidiary Time-Cap Laboratories, Inc. has received Establishment Inspection Report (EIR) from US Food & Drugs Administration for the audit conducted in October 2023. No 483’s were issued during the Audit.
Marksans Pharma Limited’s wholly owned subsidiary Relonchem Limited has received Marketing Authorisation for the product Cyanocobalamin 50mg film coated tablets from UK MHRA.
Marksans Pharma Limited has received final approval from US Food & Drugs Administration for its Abbreviated New Drug Application (ANDA) for Esomeprazole Magnesium Delayed- Release Capsules USP, 20 mg (OTC).
India Ratings and Research Private Limited (a Fitch group company) has upgraded Marksans Pharma Limited’s bank facilities’ ratings as follows:-
| Instrument Type | Size of Issue (million) |
Rating/Outlook | Rating Action |
|---|---|---|---|
| Fund-based limits | INR 1,000 | IND A+/Positive | Upgraded |
| Non-fund-based limits | INR 770 | IND A1+ | Upgraded |
Marksans Pharma Limited has received final approval from the US Food and Drug Administration (“FDA”) for its Abbreviated New Drug Application ("ANDA") for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg, over the counter ("OTC") bioequivalent of Advil Dual Action Tablets 250 mg/125 mg.
Marksans Pharma Limited has received USFDA approval for Guaifenesin Extended-Release Tablets (OTC).
Marksans Pharma Ltd. has completed the acquisition of a manufacturing site from Tevapharm India in Plot No. Al, Phase l-A, Verna Industrial Estate, Verna, Goa 403722, India.